TehOChris
2021-08-11
Nivavax over both
Why Shares of BioNTech Were Falling Today
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":892188536,"tweetId":"892188536","gmtCreate":1628643875025,"gmtModify":1633745474676,"author":{"id":3582343092162434,"idStr":"3582343092162434","authorId":3582343092162434,"authorIdStr":"3582343092162434","name":"TehOChris","avatar":"https://static.tigerbbs.com/e30ddf46446866173986a5c85e5f4e88","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nivavax over both</p></body></html>","htmlText":"<html><head></head><body><p>Nivavax over both</p></body></html>","text":"Nivavax over both","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/892188536","repostId":1134501157,"repostType":4,"repost":{"id":"1134501157","pubTimestamp":1628642716,"share":"https://www.laohu8.com/m/news/1134501157?lang=&edition=full","pubTime":"2021-08-11 08:45","market":"us","language":"en","title":"Why Shares of BioNTech Were Falling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1134501157","media":"The Motley Fool","summary":"Researchers might have found some difference between mRNA vaccine makers.\nWhat happened\nShares of Bi","content":"<p><i>Researchers might have found some difference between mRNA vaccine makers.</i></p>\n<h3><b>What happened</b></h3>\n<p>Shares of <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.</p>\n<p>The effectiveness of BioNTech's vaccine, developed with <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.</p>\n<h3><b>So what</b></h3>\n<p>With so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.</p>\n<h3><b>Now what</b></h3>\n<p>It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. It's been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.</p>\n<p>The move today couldn't have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenuethis year.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Shares of BioNTech Were Falling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Shares of BioNTech Were Falling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-11 08:45 GMT+8 <a href=https://www.fool.com/investing/2021/08/10/why-shares-of-biontech-are-falling-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Researchers might have found some difference between mRNA vaccine makers.\nWhat happened\nShares of BioNTech SE were down nearly 7% today after two studies of more than 50,000 patients in the Mayo ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/why-shares-of-biontech-are-falling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/10/why-shares-of-biontech-are-falling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134501157","content_text":"Researchers might have found some difference between mRNA vaccine makers.\nWhat happened\nShares of BioNTech SE were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna, Inc.'s vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.\nThe effectiveness of BioNTech's vaccine, developed with Pfizer, was only 42% during July, according to the study, compared to 76% for Moderna. The numbers were calculated at a time that delta has become the dominant strain infecting Americans. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.\nSo what\nWith so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.\nNow what\nIt may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary. It's been reported that the agencies could authorize them for the 7 million immunocompromised Americans as soon as this month.\nThe move today couldn't have been all about the data, though. Moderna shares fell almost 6%. Investors will need to watch for any updates as the studies go to peer review. As it stands, Moderna and BioNTech expect $20 billion and $18.6 billion, respectively, in vaccine revenuethis year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":83,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":15,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/892188536"}
精彩评论